DAS28-ESR Remission | EULAR Good Response | Boolean Remission | |||||
---|---|---|---|---|---|---|---|
OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | ||
Sex | Female vs male | 0.74 (0.625–0.877) | 0.0005 | 0.856 (0.725–1.012) | 0.0681 | 1.047 (0.841–1.303) | 0.6825 |
Age | Per 10-yr increase | 0.874 (0.829–0.921) | < 0.0001 | 0.896 (0.851–0.944) | < 0.0001 | 0.957 (0.897–1.022) | 0.1933 |
Body weight | ≥ 40 vs < 40 kg | 1.360 (1.006–1.838) | 0.0453 | 1.347 (1.019–1.780) | 0.0363 | 1.801 (1.089–2.978) | 0.0219 |
Duration of disease | 2–10 vs < 2 yrs | 0.974 (0.795–1.194) | 0.8008 | 0.847 (0.690–1.040) | 0.1136 | 0.935 (0.737–1.185) | 0.5785 |
≥ 10 vs < 2 yrs | 0.847 (0.673–1.066) | 0.1562 | 0.747 (0.594–0.940) | 0.0127 | 0.610 (0.458–0.814) | 0.0008 | |
Steinbrocker stage | III + IV vs I + II | 0.722 (0.615–0.847) | < 0.0001 | 0.771 (0.658–0.903) | 0.0013 | 0.736 (0.601–0.901) | 0.0030 |
Steinbrocker class | 3 + 4 vs 1 + 2 | 0.652 (0.557–0.765) | < 0.0001 | 0.709 (0.611–0.823) | < 0.0001 | 0.630 (0.490–0.809) | 0.0003 |
Previous use of biologics | 1 agent vs none | 0.621 (0.537–0.719) | < 0.0001 | 0.669 (0.579–0.774) | < 0.0001 | 0.615 (0.512–0.739) | < 0.0001 |
2 agents vs none | 0.494 (0.409–0.596) | < 0.0001 | 0.566 (0.472–0.679) | < 0.0001 | 0.407 (0.310–0.536) | < 0.0001 | |
MTX use (concomitant druga) | Present vs absent | 1.158 (1.013–1.323) | 0.0314 | 1.148 (1.008–1.308) | 0.0372 | 0.903 (0.759–1.075) | 0.2507 |
Corticosteroid use (concomitant druga) | 0–5 mg/dayb vs none | 0.815 (0.697–0.952) | 0.0099 | 0.932 (0.798–1.088) | 0.3702 | 0.679 (0.562–0.819) | < 0.0001 |
> 5 mg/dayb vs none | 0.564 (0.470–0.678) | < 0.0001 | 0.641 (0.536–0.766) | < 0.0001 | 0.412 (0.320–0.530) | < 0.0001 | |
NSAID use (concomitant druga) | Present vs absent | 0.865 (0.757–0.988) | 0.0325 | 0.786 (0.689–0.896) | 0.0003 | 0.692 (0.584–0.820) | < 0.0001 |
DAS28-ESR (at baseline) | Per 1-pt increase | 0.628 (0.595–0.663) | < 0.0001 | 0.794 (0.755–0.835) | < 0.0001 | 0.745 (0.696–0.796) | < 0.0001 |
↵a Concomitant use at any timepoint during the observation period, including baseline.
↵b Dose is prednisolone equivalent. DAS28-ESR: Disease Activity Score based on 28-joint-erythrocyte sedimentation rate; EULAR: European League Against Rheumatism; MTX: methotrexate; NSAID: nonsteroidal antiinflammatory drug.